Atara Biotherapeutics (ATRA) Change in Accured Expenses (2013 - 2026)

Atara Biotherapeutics (ATRA) has 14 years of Change in Accured Expenses data on file, last reported at -$642000.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 118.38% year-over-year to -$642000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9.5 million (down 195.5% YoY) and the FY2025 annual result came in at -$5.3 million, up 57.47% from the prior year.
• Change in Accured Expenses improved to -$642000.0 in Q1 2026, from -$796000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $9.6 million in Q4 2022 to a low of -$8.7 million in Q1 2023.
• A 5-year average of -$1.3 million and a median of -$1.8 million in 2024 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 227.38% — and 2023, when it sank 1434.39%.
• Tracing ATRA's Change in Accured Expenses over 5 years: stood at $9.6 million in 2022, then sank by 130.29% to -$2.9 million in 2023, then advanced by 29.3% to -$2.1 million in 2024, then soared by 61.32% to -$796000.0 in 2025, then increased by 19.35% to -$642000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$642000.0 (Q1 2026), -$796000.0 (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.